BRCA1/2

Treatment options improving for Cholangiocarcinoma

By Steve|2024-10-11T16:12:25+10:00October 15th, 2018|Categories: All, Immunotherapy, Z-Legacy|Tags: ABC-02, ARID1A, BAP1, BAY1436032, BRAF, BRCA1/2, Chemotherapy, Cyramza, dmmr, EGFR, epigenetic, FGFR2, Gem/Cis, GENOME, HER2 amplification, IDH1, IDH1/2, immunotherapy, Kelly, KEYNOTE-158, Keytruda, Lynparza, MEK, MET, MMR, olaparib, Oncologists, ramucirumab, TAS-120, TP53, treatment, TreeTopp, VEGFR, VEGFR2|

Cholangiocarcinoma Treatment lmproving

By Steve|2024-10-11T16:13:34+10:00August 15th, 2018|Categories: All, Clinical Trials, Immunotherapy, Z-Legacy|Tags: ARID1A, BRCA1/2, dmmr, HER2 amplification, Keytruda, Pembrolizumab, TP53|

Need Help Now?

Connect with Steve
+61 415 153 522
steve@cholangio.org

Connect with Claire
+61 431 180 783
claire@cholangio.org

Connect With Us

Patient-led. Built by survivors. Powered by action.

Cholangiocarcinoma Foundation Australia is registered as a charity with the Australian Charities and Not-for-Profits Commission (ACNC).
Cholangiocarcinoma Foundation Australia has Deductible Gift Recipient (DGR) status with the Australian Tax Office.
Donations over $2 or more are tax-deductible.
ABN: 93665038102